Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Atherosclerotic cardiovascular disease remains a leading cause of mortality worldwide.
• Statin therapy is a cornerstone in managing dyslipidemia and preventing cardiovascular events.
• The efficacy of fluvastatin in patients with average cholesterol levels post-stent implantation requires further elucidation.

Purpose of the Study:

• To evaluate the long-term impact of fluvastatin on adverse atherosclerotic cardiac events.
• To assess the effect of fluvastatin on lipid profiles in patients undergoing stent placement.
• To determine the risk reduction of major adverse cardiac events with fluvastatin compared to placebo.

Main Methods:

• The Lescol Intervention Prevention Study (LIPS) enrolled 847 patients with average cholesterol levels treated with stents.
• Patients were randomized to receive either fluvastatin (n = 417) or a placebo (n = 430).
• Outcomes were assessed over a 4-year follow-up period, focusing on cardiac death, myocardial infarction, and revascularization.

Main Results:

• Fluvastatin significantly reduced total cholesterol and low-density lipoprotein cholesterol levels.
• A 30% decrease in the risk of first adverse atherosclerotic cardiac events was observed in the fluvastatin group compared to placebo (p = 0.03).
• The 95% confidence interval for the risk reduction was -49% to -3.4%.

Conclusions:

• Long-term fluvastatin treatment is effective in reducing adverse atherosclerotic cardiac events in patients with average cholesterol levels post-stent placement.
• Fluvastatin demonstrates significant lipid-lowering effects and contributes to secondary cardiovascular event prevention.
• The study supports the use of fluvastatin as part of a comprehensive management strategy for patients at risk of cardiovascular events.